Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice

Détails

ID Serval
serval:BIB_46F6461CD001
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Titre
Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice
Périodique
European Journal of Gastroenterology and Hepatology
Auteur(s)
Felley  C., Michetti  P.
ISSN
0954-691X (Print)
Statut éditorial
Publié
Date de publication
12/2003
Volume
15
Numéro
12
Pages
1253-5
Notes
Comment
Journal Article --- Old month value: Dec
Résumé
Current treatments of inflammatory bowel diseases are limited either by their lack of efficacy or their potential toxicity. In recent years, major advances have been obtained by the development of biological therapies. However, these types of treatment are systemic and can lead to serious adverse events. The new venue of local biological treatments would be most welcome. In this issue of the Journal, Castagliuolo et al. show that lymphocytes engineered to produce TGF-beta1 can reverse dinitrobenzene sulphonic acid-induced colitis in mice. These engineered lymphocytes selectively accumulate in the intestinal mucosa due to the homing properties of their alpha4beta7 integrins, a ligand for MAdCAM1. A local treatment restricted to the inflamed mucosa can thus be obtained. This opens a brand new area of research with the hope of restoring the immunoregulatory balance selectively in the inflamed tissues.
Mots-clé
Animals Benzenesulfonates Colitis/chemically induced/*therapy Gene Therapy/*methods Lymphocyte Transfusion/*methods Lymphocytes/metabolism Mice Transforming Growth Factor beta/*biosynthesis Transforming Growth Factor beta1
Pubmed
Web of science
Création de la notice
25/01/2008 16:59
Dernière modification de la notice
03/03/2018 16:48
Données d'usage